Fri 9 Jul 2021 Interview with Pierre Billardon, DORC CEO | Ophthalmology Management, July 2021 In an interview with Ophthalmology Management magazine DORC CEO Pierre Billardon said he was satisfied with the 2020 results and expects...
Wed 16 Jun 2021 DORC launches EVA EquiPhaco™ angled needles | NEW DORC introduces EVA EquiPhaco™ angled needles....
Fri 21 May 2021 DORC launches new disposable phaco fragmentation needles | NEW DORC is pleased to introduce the new disposable phaco fragmentation needles in 20G and 23G to complement its existing range of reusable phaco...
Thu 22 Apr 2021 DORC launches EVA Trocar cannula system | Press Release DORC is launching the new EVA Trocar cannula system (marketed as EVA AVETA™ outside US). EVA Trocar is the first system to feature the pa...
Thu 28 Jan 2021 DORC announces Health Canada approval of TissueBlue™ for Staining of the ILM During Vitreoretinal Surgery – the first Health Canada approved product for this indication. | Press Release DORC announces Health Canada approval of TissueBlue™ for Staining of the ILM During Vitreoretinal Surgery – the first Health Canada ap...
Mon 29 Jun 2020 DORC launches new range of EVA EquiPhaco™ needles and sleeves | new DORC is excited to launch our new range of EVA EquiPhaco needles and sleeves. The EVA EquiPhaco™ range will deliver superior performance and ...
Fri 3 Apr 2020 CEO statement on coronavirus | COVID-19 The COVID-19 pandemic is having an unprecedented impact on our world, and clearly our first thoughts are with those people affected by this virus. ...
Mon 7 Oct 2019 DORC obtains 510k clearance for launch of the EVA UPGRADED enhancements in the USA | NEWS DORC is proud to announce 510k clearance for a significant range of enhancements to the EVA surgical system....
Mon 19 Aug 2019 DORC at EURETINA 2019 | INVITATION Don't hesitate to join these exciting events - see you in Paris! ...